Cellular Biomedicine Group, Inc.

Form 3 July 08, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

A Leung Pak To

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

07/02/2014

Officer

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

1902-03 BANK OF AMERICA TOWER, 12 HARCOURT

ROAD, CENTRAL

1. Title of Security

Common Stock

(Instr. 4)

(Street)

\_X\_ 10% Owner Director

(Check all applicable)

Other (give title below) (specify below)

Cellular Biomedicine Group, Inc. [CBMG]

6. Individual or Joint/Group

Filing(Check Applicable Line) Form filed by One Reporting

Person

X Form filed by More than One

Reporting Person

HONG KONG, F4Â 00000

(City) (State) (Zip)

> 2. Amount of Securities Beneficially Owned

(Instr. 4)

554,777

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership Form: (Instr. 5)

Direct (D) or Indirect (I)

(Instr. 5)

Through Full Moon Resources Ι Ltd., which is 100% owned by

Mr. Leung (also sole director). (1)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

2. Date Exercisable and Expiration 3. Title and Amount of Date

Securities Underlying

5. Conversion Ownership

6. Nature of Indirect Beneficial

## Edgar Filing: Cellular Biomedicine Group, Inc. - Form 3

(Instr. 4)	(Month/Day/Year)  Date Exercisable Expiration	Derivative (Instr. 4) on Date Title	Amount or Number of Shares	or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)
Option to acquire shares of Common Stock	07/02/2014 <sup>(2)</sup> 07/02/2	2017 <sup>(2)</sup> Commo Stock	n 1,000,000	\$ 8	I	Through Venture Garden Limited, which is 100% owned by Mr. Leung (also sole director). (1)

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
reporting owner runner runness	Director	10% Owner	Officer	Other	
Leung Pak To 1902-03 BANK OF AMERICA TOWER 12 HARCOURT ROAD, CENTRAL HONG KONG, F4 00000	Â	ÂΧ	Â	Â	
Full Moon Resources Ltd 1902-03 BANK OF AMERICA TOWER 12 HARCOURT RD, CENTRAL HONG KONG, F4 00000	Â	Â	Â	Controlled by a 10% Owner	
Venture Garden Ltd 1902-03 BANK OF AMERICA TOWER 12 HARCOURT RD, CENTRAL HONG KONG, F4 00000	Â	Â	Â	Controlled by a 10% Owner	

# **Signatures**

/s/ Pak To Leung 07/08/2014

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Full Moon Resources Limited expressly disclaims beneficial ownership of the shares of Common Stock of the Issuer beneficially owned (1) by Venture Garden Limited. Venture Garden Limited expressly disclaims beneficial ownership of the shares of Common Stock of the Issuer beneficially owned by Full Moon Resources Limited.
- The Option is subject to a mandatory exercise provision, pursuant to which the Issuer has the option to require the unexercised portion of the Option be exercised in full within 14 days of the date on which a Triggering Condition is satisfied. A "Triggering Condition" is defined as an event in which, at any time after January 2, 2016, the VWAP of the shares of the Company on each trading day is greater than US\$12 for a consecutive period of 20 trading days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Reporting Owners 2

# Edgar Filing: Cellular Biomedicine Group, Inc. - Form 3